Podcast appearances and mentions of David Kendall

We’re pulling over on our road trip through season 6 to revisit some of our favorite Boy Meets World episodes, now with special guests! First up, BMW Hall of Fame director David Kendall is here to throw it back to season 2, and just like Shawn knocking on Turner’s door, we’re looking for a place to call “Home.” This is the first episode where David served as the director, writer AND showrunner, so he shares some triple threat BTS secrets about how Shawn’s storyline developed over time. David also helps us understand what makes a truly “good” director, and we get an answer on what REALLY was in the brown bag that Kat left at Turners. All on a new throwback episode of Pod Meets World! Follow @podmeetsworldshow on Instagram and TikTok!See omnystudio.com/listener for privacy information.

More proof news is here! Following the April 2025 Genetic Evaluations, we learn more about the expansive Colored Breed offering from STgenetics®. In this STtalks we delve into significant advancements in the Jersey, Brown Swiss, Ayrshire, Guernsey and STamina™ breeds, highlighting outstanding bulls like OLEY, GORMAN, JUDSON-P, LASPADA, TESLA, OTHELLO, CHECKMATE, and many more. We also learn about STgenetics® Chromosomal Mating Program®, Ultraplus High Purity™ gender-sorted semen and STgenetics® commitment to technological advancements and breeder success!00:00 Introduction 00:36 Jersey Breed Genetic Evaluations02:36 Highlighting Top Jersey Bulls12:40 Jersey Chromosomal Mating Program®17:02 Brown Swiss Breed Insights17:58 Spotlight on Brown Swiss Bulls24:14 Ayrshire Breed Highlights26:57 STamina™ Lineup and New Releases31:35 Final Thoughts and Conclusion

This week's Chairman's Report is guest written by Dr. David Kendall, a professor of economics and finance at the University of Virginia's College at Wise. In it, Professor Kendall makes a compelling case against the income tax from a moral point of view.

Proof news is here! Following the April 2025 Genetic Evaluations, we had a lot to catch up on and learn. This STtalks covers the impact of the recent base change, changes in TPI and NM$, and the performance of breed leading sires like CAPTAIN, THORSON and more. Additionally, this group discus's the promising young bulls in the STgenetics® portfolio and how pairing this elite group of genetics with the correct technology can lead to exponential performance and profitability for a dairy farm. We dive into more of the results on both the proven sire and young GTPI lists as well as other areas that bring diversity and success to the Holstein breeder.00:00 Introduction00:34 Understanding the Base Change02:40 Impact on TPI and NM$05:10 Chromosomal Mating® and Its Importance06:05 Proven Sire List Highlights07:52 THORSON: A Newly Proven Sire10:40 Diversity in the Top TPI Proven List14:49 Exciting Young Bulls in the Lineup17:29 Future of the Bull Program19:24 Traits and Indexes That Matter23:01 Eco$: A Progressive Tool24:50 Final Thoughts and Conclusion

It's inevitable that any discussion of President Trump's plan to eliminate the income tax will be tainted with politics.Consequently, the FAIRtax Guys asked economist David Kendall to take a look at income taxes vs. consumption taxes strictly within the realm of the science of economics.  When you strip away the politics, there's clearly a good way and a bad way to fund the federal government.

STgenetics® Chromosomal Mating® program goes beyond the average breeding decision, and in this STtalks we delve into the core concepts and benefits of this technology in a two-part series. To share their expertise we have Sara Westberry, David Kendall, Adam Taiti and Ron Jackson all on to gives us their insights and experiences. In this first part we learn more about how mating programs benefit dairy farmers today, how Chromosomal Mating® delivers a unique data-driven approach to success and how this can push herd genetics to new heights while controlling inbreeding.

Is asking Congress to pass the FAIRtax a bridge too far? Not necessarily. See why in this week's Chairman's Report guest written by economics professor Dr. David Kendall.

David Kendall sits down with David Oscar Markus to discuss the impeachment trial of President Bill Clinton.Independent counsel, impeachment hearings, infidelity. No, we aren't talking about Donald Trump. Instead, we head back to the late 90s to discuss David Kendall's incredible representation of President Bill Clinton. The high stakes showdown between Kendall and independent counsel Ken Starr was must-see TV, and we get into the fascinating stories from that era in this episode of For the Defense.

Join us in our next STtalks as we learn more about the slick gene and how identifying this allele can benefit not only the cattle in heat stress environments but the dairy breed as a whole. We dive into production, reproduction and the multiplication of the slick gene with David Kendall, STgenetics® Director of Genetic Development within this exciting STtalks! 00:00 Introduction00:43 Understanding the Slick Gene01:46 Breeds with the Slick Allele03:37 Benefits of the Slick Gene in Heat Stress Environments04:47 Research and Discoveries on the Slick Gene06:40 Reproductive Health and the Slick Gene08:02 Testing and Multiplying the Slick Gene10:09 Future Research and Exciting Discoveries12:17 Conclusion and Closing Remarks

This week we are joined by ‘Ned's Declassified' director David Kendall! David has worked on a plethora of kid's tv shows such as ‘Even Stevens', ‘Stuck In The Middle', ‘A Pair of Kings', and secrets are revealed when David is asked which kids cast was the best and worst to work with! David talks about what it is like to watch the child actors grow up, and what advice he would give to parents wanting to put their children in show business. David also dishes on his experience directing the very first episode of Ned's after they had already filmed the unaired pilot.  Why was Lindsey scared of David? Does David think there should be Ned's Reboot?? And has David ever been fired from a directing job??? Follow @NedsDeclassifiedPod on Instagram & Facebook, and @NedsPod on TikTok. Want access to weekly bonus videos, exclusive behind-the-scenes content and more? Join our Patreon now at patreon.com/NedsPod. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This week we are joined by ‘Ned's Declassified' director David Kendall! David has worked on a plethora of kid's tv shows such as ‘Even Stevens', ‘Stuck In The Middle', ‘A Pair of Kings', and secrets are revealed when David is asked which kids cast was the best and worst to work with! David talks about what it is like to watch the child actors grow up, and what advice he would give to parents wanting to put their children in show business. David also dishes on his experience directing the very first episode of Ned's after they had already filmed the unaired pilot. Why was Lindsey scared of David? Does David think there should be Ned's Reboot?? And has David ever been fired from a directing job???Follow @NedsDeclassifiedPod on Instagram & Facebook, and @NedsPod on TikTok.Want access to weekly bonus videos, exclusive behind-the-scenes content and more? Join our Patreon now at patreon.com/NedsPod.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Message from Devo Kritzinger on July 6, 2024

In this session, we delve into the art and science of hiring the perfect sales leader for boutique professional service firms. Join Collective 54 member David Kendall, President & CEO at KAI Partners, as we discuss the unique challenges these firms face, the qualities that define a successful sales leader in this niche, and practical strategies to identify and attract top talent. Whether you're in the early stages of building your sales team or looking to elevate your firm to the next level, join us for expert advice and real-world examples to guide you through the hiring process.

In the latest episode of STtalks we discuss the genetic changes we saw during the December 2023 Genetic Evaluations, most notably with JUI and JPI in the Jersey Breed. David Kendall, STgenetics Director of Genetic Advancement joined us to share his thoughts on these new changes as well as the correlation between DPR and CCR.

In the latest episode of STtalks we speak with David Kendall to learn about the Slick Gene! From the history behind this gene, its benefits and what STgenetics is doing from a research stance, we learn a lot from David on a unique bovine gene.

In the latest episode of STtalks we discuss the successful August 2023 Colored Breeds Genetic Evaluation for STgenetics®. From the steady hold the Jersey Program saw, to the new releases in multiple breeds and the consistency the future of these programs will see, we cover a lot of great information for Colored Breeds enthusiasts in this episode!

In the latest episode of STtalks we discuss the successful August 2023 Genetic Evaluation for STgenetics®. With Captain being named the #1 TPI Sire of the breed to our new releases, the Delta-Lambda influence and more, we cover all that happened in this proof run in this STtalks episode.

Christopher speaks to Dr Ella Simpson @TheHalfArtist, David Kendall @manwithbooks, Marek Kazmierski @MarekKazmierski and callers about teaching writing in custodial settings and about preparing prisoners for freedom through writing.

Writer, Producer & Director David Kendall has some real, never heard before Boy Meets World intel! Since he was inserted into the show's creative brain trust by the network for Season 2, he knows absolutely everything about the transformation from warm cozy blanket to “The Horny Teen Era.”  Who was on the chopping block? What was the aged up directive moving into high school? And WHAT DID THEY ALMOST CHANGE THE NAME TO? Kendall has the answer and spills all the beans.See omnystudio.com/listener for privacy information.

This week's Chairman's Report is a reprint of an article written by economics professor David Kendall. It offers some insightful analysis of why the FAIRtax has languished in Congress for 23 years, and what we FAIRtax advocates must do to eventually get it passed.

STgenetics® sits down at the World Brown Swiss Conference with David Kendall, STgenetics® Director of Genetic Advancement to discuss his presentation, The Need for Speed, and what it has to do with the Brown Swiss Breed.

Writer-Producer-Director David Kendall talks about his time on Growing Pains, Hannah Montana, iCarly and his new film Steppin into the Holiday.

Sit down with STgenetics and two of our leading genetic managers, David Kendall and Kevin Ziemba to hear about what all transpired in our color breed portfolio following the April genetic evaluations. We cover index and type changes we saw and analyze the sires that stood out to us this proof run

We sit down with STgenetics® Dairy Program Manager, Dan Carroll, Director of Genetic Advancement, David Kendall and Advancement Team Member, Tim Rauen to learn about what all happened with the April 2022 Holstein Proof Run. From the reissue and our current genetic portfolio to what we're seeing with daughters, we cover it all in the latest STtalks!

David Kendall, a fellow at the Vancouver-based Outer Space Institute and former director-general of space science and technology at the Canadian Space Agency

Our winners from the past three weeks--Josh Wennrich, David Kendall, and Steve Homer--are back again to see who will be crowned the winner of wave 28 of TW: Blitz!

This new episode features two of STgenetics® Brown Swiss enthusiasts, David Kendall and Kevin Ziemba! David and Kevin talk about the history of STgenetics® Brown Swiss program, what the portfolio looks like today and the excitement we have coming down the pipeline!

Continuing on in wave 28, we've got Jane Hansen, David Kendall, and Chad Birnbaum here this week to battle it out. Listen in, play along, and see who will be moving on!

In part two of his interview with FAIRtax Power Radio, economics professor David Kendall explores some of the alternatives that have been suggested as replacements for the income tax including a flat tax and a value added tax. Then, he has some rather interesting comments about repealing the 16th Amendment.

This is the first of a two-part interview with economics professor David Kendall. In this episode, Professor Kendall addresses what's wrong with the income tax from an economist's perspective.

Sit down with STgenetics® Dairy Program Manager, Dan Carrol, Director of Genetic Advancement, David Kendall and Advancement Team Member, Tim Rauen to learn all about the December Holstein Proof Run. From Proven Sires and Young Genomic Sires to Index spreads, we cover it all.

This week's Chairman's Report features an economics professor, David Kendall. Seventeen years ago, he wrote to the newly formed President's Advisory Panel on Federal Tax Reform urging them to adopt the FAIRtax. Eighty professional economists endorsed the letter, but the Panel paid them no attention. Seventeen years later, the FAIRtax is still the best replacement for the Federal income tax. We can't give up now.

Episódio 119, de Dias Úteis, um podcast que lhe oferece poesia pela manhã, de segunda a sexta-feira. Por vezes não apenas poesia, por vezes não apenas nos dias úteis...  Durante as próximas semanas, em modo veraneante, trazemos textos que podem levar para longe, sem sair do lugar. Para hoje, viagem de Inglaterra até aos Estados Unidos da América, com o poema de Robert Penn Warren pela voz de David Kendall ( http://www.davidkendall.co.uk/ ) Tema musical original de Marco Figueiredo, com voz de José Carlos Tinoco. Design de Catarina Ribeiro. Edição de Filipe Lopes. Saiba mais sobre os nossos projectos em www.assdeideias.pt. Procure os poemas lidos e muitos outros, adquirindo livros através da ReLi, Rede Independente de Livrarias (https://www.reli.pt) e apoie assim o sector livreiro em Portugal.

This year marks the 100th anniversary of the discovery of insulin as a treatment for diabetes. For the past several decades, innovation in the diabetes space has reached unprecedented levels. Dr. David Kendall has been a key player in this space, and shares the latest insights and developments.  Press play to learn: The key difference between glucose and glucagon What causes severe hypoglycemic events in the body How dasiglucagon works, how it can be administered, and who is a good candidate for it Dr. David Kendall is a senior global medical advisor at Zealand Pharma, a company that for decades has been committed to innovation in the peptide therapeutics space. By modifying naturally-occurring peptides—the tiny building blocks of proteins and enzymes—the team at Zealand is using them as treatments for human diseases. The primary focus is on metabolic diseases, like diabetes and certain GI diseases. For example, Zealand has created dasiglucagon, a now FDA-approved analog of naturally-occurring glucagon designed to treat episodes of severely low blood sugar, commonly known as hypoglycemia. Dr. Kendall explains the function and benefits of dasiglucagon, and when it can be used as a lifesaving measure in those with insulin-requiring diabetes and hypoglycemic events. He also discusses one of Zealand's latest projects, a bihormonal artificial pancreas system that provides insulin and counteractive glucagon to help people with the long-term management of diabetes. Tune in for all the details and visit https://www.zealandpharma.com/ to learn more.

Space sustainability includes many facets. There's the science, and there's the policy. However, both have to be part of the conversation to achieve objectives. Space to Grow hosts Chris Blackerby and Charity Weeden spoke with esteemed physicist and space policy leader Dr. David Kendall. Dr. Kendall was the Chair of the United Nations Committee on Peaceful Uses of Outer Space (COPUOS), the Director-General of the Canadian Space Agency, and a faculty member at the International Space University.The hosts asked Dr. Kendall if it was harder to be a scientist or diplomat. “They are both challenging in different ways. Science is a singular activity that requires full immersion. Diplomacy puts you out there talking to people.”Dr. Kendall had no formal plans to transition, but a conversation with his wife made him apply to become the Director-General of the Canadian Space Agency. “Then I saw the other side of the coin and how decisions are made. The space business really is a team effort, globally.”“The legal and scientific committees don't talk to each other but must. We also need to find a way for the commercial sector voices to be heard. And we need to move a lot faster.” -Dr. David KendallOne of Dr. Kendall's most significant contributions to space policy was his work on the 21 Long-Term Sustainability of Outer Space Activities guidelines. He was part of the working group and then the chair. It required all nation-state approval and was finally approved in 2019, with all 90 members saying yes.“Creating 21 new ways of working together was an accomplishment. But there's more to do on many issues like active debris removal and space traffic management,” Dr. Kendall said.After serving as chair, Dr. Kendall highlighted the next challenges that the organization needed to consider. “The legal and scientific committees don't talk to each other but must. We also need to find a way for the commercial sector voices to be heard. And we need to move a lot faster.”

After decades with just one not-so-user-friendly option, another shelf stable rescue glucagon enters the market. It’s called Zegalogue, FDA-approved and coming soon in both an auto injector and a prefilled syringe. One additional future use will be in the Beta Bionics iLet pump with two chambers – one for the insulin and one for this glucagon. Stacey talks with Frank Sanders, President of Zealand Pharma U.S. and Dr. David Kendall, Senior Global Medical Advisor. This interview covers everything from the use of Zegalogue now to cost and a look at how far treatments have come. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Episode transcription below Click here for iPhone      Click here for Android   Stacey Simms  0:00 Diabetes Connections is brought to you by Dario health manage your blood glucose levels increase your possibilities by Gvoke Hypopen, the first premixed autoinjector for very low blood sugar and by Dexcom keeping you in control with an integrated system for diabetes management.   Announcer  0:21 This is Diabetes Connections with Stacey Simms.   Stacey Simms  0:27 This week after decades with just one not so user friendly option, another rescue glucagon enters the market. It's called Zegalogue, one future use will be a pump with two chambers, one for the insulin and one for glucagon.   Frank Sanders  0:43 So, with insulin being one side of that equation, when glucose does go lower, instead of simply shutting off the insulin and waiting for it to clear from the system, you have counterbalance, or the ability to counter regulate with the glucagon infusion in small little delivery boluses.   Stacey Simms  1:02 That's Frank Sanders president of Zealand pharmacy in the US, he and Dr. David Kendall, their senior global medical advisor, join me to talk about everything from the use of Zegalogue now to cost and to look at how far treatments have come. And spotting a diabetes pump in the wild never gets old. I'll tell you a quick story about what happened with us. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show. I'm so glad to have you all here we aim to educate and inspire about diabetes with a focus on people who use insulin. My son Ben in the state is 14 years ago with type one, my husband lives with type two, I don't have diabetes, I have a background in broadcasting. And that is how you get this podcast. Thank you for the great feedback out last week's not really a bonus episode. But second episode that I've been doing, I changed it up again. And I released Diabetes Connections in the news, many of you have already listened to it. But I'm thrilled that I'm getting reaction. I don't even mind if it's constructive criticism or just I hate it. I really would like to know what you think I'm experimenting throughout the month of May. We're going to do four episodes of in the news live on Facebook first on Wednesdays at 430. And then a podcast episode that will turn around probably Thursday night or Friday morning and get you caught up on the week's news. So please let me know we have a post going in the Facebook group as well. You know, six years ago, I launched this podcast and I liked that I'm still experimenting with it. And I hope that you do too because the idea is just to get you good information that you can use whether it's long format like we're going to do today, or short headlines, like I'm trying with that in the news stuff. And of course we throw in some personal stories here and there. And after this interview, I'll tell you about Benny's first wrestling match and how you know we spotted diabetes in the wild. Alright, my guests this week are from Zealand Pharmaceutical, they just got FDA approval a few weeks ago for Zegalogue. The newest shelf stable emergency glucagon, you know, it really is incredible when you think about it the last 40 or 50 years more than that all we've had for emergency glucagon has been the stuff in the red or orange emergency box, the kind that you have to reconstitute yourself you know, and studies show that most people even those trained you don't use it very well especially under stress. And now we have three options vaccine me and G vo hypo pen and Vega log. You're going to hear from Frank Sanders. He's the president of Zealand pharmacy and Dr. David Kendall. He is their senior global medical advisor Frank Sanders has been in the pharmaceutical industry for more than 25 years. He has been with a company called therapeutics he's been with Johnson and Johnson's pharmaceutical arm many of you are familiar with Janssen pharmaceutical. He's been with GlaxoSmithKline and Dr. David Kendall has held many leadership positions in the diabetes community including at mankind at Lilly at the American Diabetes Association and at the International Diabetes Center in Minneapolis. Dr. Kendall and I also go way off topic toward the end because he served as a clinical investigator with the dcct and edic trials here homeless tourists will remember those evidence based on hope episode, which is one of my all time favorites, I will talk about the DCC T and edic trials at the drop of a hat. And I was so excited that Dr. Kendall can too Okay, quick disclosure gotta tell you, your competitor to this product is a sponsor of this show. In fact, I'm about to read an ad from them. But as you know, Diabetes Connections is here to help you get information about the diabetes community and I don't limit who we talk to because of who spends money on advertising. Now on the flip side, the advertisers are also on board with all of that so I give them a lot of credit to longtime listeners are familiar with all of this, but just in case, I like to talk about it every time and let's keep things on the up and up. Okay, let me tell you then Diabetes Connections is Brought to you by Gvoke Hypopen and our endo always told us that if you use insulin, you need to have emergency glucagon on hand as well. Low blood sugars are one thing, we're usually able to treat those with fast acting glucose tabs or juice. But a very low blood sugar can be frightening which is why I am so glad there's a different option for emergency glucagon. It's Gvoke Hypopen . Gvoke Hypopen is pre mixed and ready to go with no visible needle, you pull off the red cap and push the yellow end onto bare skin and hold it for five seconds. That's it, find out more go to Diabetes connections.com and click on the Gvoke logo. Gvoke shouldn't be used in patients with pheochromocytoma or insulinoma. Visit gvokeglucagon dot com slash risk. Frank Sanders, Dr. Kendall, thank you so much for joining me today. I'm really interested to learn more about this. I appreciate you being here.   Unknown Speaker  5:50 Thank you. We're glad to be here as well. Yeah. Thanks so much,   Unknown Speaker  5:52 Stacy.   Stacey Simms  5:53 You got it. So Frank, let me start with you. If I could just, you know, to give us an overview a little bit. We've never talked before, if you could kind of catch me up on what Zealand is all about. And then we'll talk about Zegalogue.   Frank Sanders  6:05 Yeah, sure. Thank you for the question. I appreciate it, Stacy. So I'll start by saying that Zealand is a global biotechnology company and a world leader in peptide therapeutic development. Well, it may seem like a new company, the company was actually founded in 1998. It is headquartered in Copenhagen, Denmark. And we have our US presence and our company in our corporate office in Boston in the seaport area. So the company has approximately 330 employees worldwide. And our we believe our distinguished advantage is our unique peptide platform that allows us to design and engineer highly innovative peptide and peptide like medicines for, you know, for multiple conditions. So we have a 20 year legacy in r&d and peptide therapeutics, and we're very proud of what we've delivered.   Stacey Simms  6:50 Can you take just a second and I when we hear peptide on this podcast, we just think about that C peptide test, right? That helps figure out if it's type one or type two diabetes, what does a peptide therapeutic be?   Dr. David Kendall  7:02 I'm happy to take that one. And Frank, please feel free to chime in. But Stacy, a peptide in the common ones that I'm sure this audience knows about are things like insulin, glucagon, or modifications there. But they are very simply the proteins. In the body peptides generally referred to proteins which are made up of these building blocks we call amino acids, usually up to 25 to 50 of these amino acid segments plugged together glucagon, which we'll be talking about today, and LC glucagon is made up of 37 of these building blocks. So peptides that are commonly known are just those proteins that circulate in the body or makeup, the structure of the body.   Stacey Simms  7:46 Alright, let's talk about Zegalogue. I think most of my listeners are familiar with the concept of needing emergency glucagon sometimes, but tell me the specifics about Zegalogue Frank Sanders  7:56 So the clinical profile Zegalogue  is compelling. And we are actually out in active dialogue with payers right now. And we have been in dialogue with healthcare professionals and patients around the profile through market research before we execute a full product launch following approval. And the approval of Zegalogue is based on the results from three randomized, double blind placebo controlled controlled phase three trials, that's a mouthful in both children and adults with type one diabetes. And what's marketed and notable about Zegalogue is the median time to blood blood glucose recovery of 10 minutes that we've seen across all three phase three trials. More specifically, in the phase three trials. 99% of adults recovered in 15 minutes in the main adult trial, and 95% of pediatric patients recovered and 15 minutes in the pediatric trials. So So we believe the dialogue offers patients and caregivers in an important new choice for the for the management of severe hypoglycemia, which is a condition where minutes obviously matter, so we're eager. So the launch the product, in just over a month and late June,   Stacey Simms  9:02 didn't take me into that study a little bit more in terms of how low people were, if you can share that.   Dr. David Kendall  9:09 Happy to do that, Stacy and as Frank mentioned, glucagon, the native peptide or protein that many people have known about, and I'm sure many of your listeners are familiar with has been around and available for treatments since the 1960s. But what Zegalogue and dasiglucagon the active molecule was able to do is make modifications in that peptide chain to ultimately lead to chemical that we felt was suitable for development that went through those clinical testing programs that Frank talked about, and specific to those trials to bring this forward as a medication that could be reviewed and approved for the treatment of severe little bunch of blood sugar, or what we call severe hypoglycemia required that in controlled fashion, taking volunteers, courageous and really volunteers to whom we are incredibly grateful to use an insulin infusion, so give insulin in their vein in a controlled way, bring their blood sugar below a specific level, usually that level is 70 milligrams per deciliter or lower, slightly higher in the studies with children, and do that in as controlled away as possible, then stop that infusion of insulin. And this is really meant Stacy to mimic what might happen in an unexpected, unanticipated severe low blood trigger event. And those individuals then are given a dose either of placebo medicine, or in the case of these studies, Sega log and its pre Approval Form dasiglucagon, and then in those same trials, not for direct comparison, but just to understand what the world was familiar with, we also gave selected individuals, the traditional glucagon from the emergency kit that many people may know, which is the one that requires that it be reconstituted, mixed up, drawn back up in a syringe and then given so the studies took experimental, low blood sugar, let's say on average, the value is just below 70. Got the dose of medication. And then we measured the so called time to recovery that Frank talked about which in all of these trials was how long it took to see that number no matter where it started to come up by 20 points. So a very consistent measure of recovery time. And as Frank said, the median time to recovery was 10 minutes across each of the three larger phase three trials. And you looked at the 15 minute time point, which is a very important one for watching loved ones recover and making sure that they either are responsive or another dose of medicine can be given 99% of adults, 95% of children had recovery   Unknown Speaker  11:55 in that time period.   Dr. David Kendall  11:56 So very important to understand how the trials were done. But ultimately, it led to our review and approval as a treatment for severe low blood sugar.   Stacey Simms  12:06 Wow, I appreciate you going through so thoroughly, I have a couple of questions, because I have a couple of friends who have gone through clinical trials for products like this. I don't know if they were specifically in this one. But as you said, You don't just sit there and say, Okay, give me all that insulin, no, I'm gonna go low. You know, we really have to thank those people. But you mentioned some of them got a placebo. So I know it was a safe environment. But what does that mean? Like they just sat there and went low for a while?   Frank Sanders  12:32 Yeah, I'm always amazed the Food and Drug Administration, their regulators are thoughtful and cautious about how these studies are designed, we are as well, in placebo, obviously, is done only in a controlled setting where we understand what the potential risks of giving, essentially, no therapy might be. But knowing that in these studies, as I said, Even though zega log is approved for the treatment of truly severe low blood sugar, these were not patients that lost consciousness couldn't manage for themselves, but in a controlled setting where we could give them an intravenous injection of glucose if we needed to, or ultimately rescue them with safety glucagon administration, these were individuals who had to understand that they were going to go low, probably feel something they felt before not necessarily feel comfortable, and then know that there was a chance they were getting just saltwater sailing, or potentially getting one of the other two therapies. And obviously, they were monitored very carefully. And we didn't allow this to go on, you know, indefinitely. They were ultimately treated either with glucose by vain or given something to eat.   Stacey Simms  13:42 I'm curious to, again, I appreciate you letting me go down this rabbit hole. There is an interesting conversation all the time in the diabetes community about letting those go. And I know some of you, as you listen gasped. But I mean, there are some times where you'll sleep through a low or you'll just won't notice although you know, you're 7075 and then you'll, you'll float back up because your liver has kicked in it. You know, I'm curious, I know, this wasn't what the study was designed to do. But was there any information from the placebo folks of them kind of recovering without treatment?   Right back to Dr. Kendall answering that question. But first Diabetes Connections is brought to you by Dario. And the bottom line is you need a plan of action with diabetes. We've been lucky that Benny's endo has helped us with that and that he understands the plan has to change as Benny gets older, you want that kind of support. So take your diabetes management to the next level with Dario health. There are published Studies demonstrate high impact results for active users like improved in range percentage within three months reduction of a one c within three months and a 58% decrease in occurrences of severe hypoglycemic events. Try Dario’s diabetes success plan and make a difference in your diabetes management. Go to my dario.com forward slash diabetes dash connections. For more proven results and for information about the plan now back to Dr. Kendall, answering my questions about those that kind of resolve on their own.   Frank Sanders  15:13 So the the proportion of people who recovered with placebo therapy was extinguishing Lilo, I will say, at least in the 15 minutes time period, by 45 minutes, either they had recovered or we allowed them to recover. I know a bit more about this, because I spent my early years of research doing these experimental low blood sugar studies. And your comment about letting the logo is not something I certainly would advise as a health care professional, but it does happen. And the risks if it's not a severe low, are often you know, an inconvenience or disrupted sleep or in some cases, complete lack of awareness. The risk there, Stacy is any low blood sugar makes a subsequent low blood sugar more likely. And the typical symptoms and responses that the body has, will diminish when the body has seen multiple episodes of low blood sugar. It's as if the body's saying I've seen this before, I'm going to quit warning you and treating it. And that, as we've learned over time is one of the risk factors for an unexpected and more serious and severe hypoglycemic event. So I would not recommend letting the logo   Stacey Simms  16:24 be either, I want to be very clear. But it is something that is discussed. It's not as though that's something that to be very clear as you listen and to you all to, it wasn't something I said in that I endorse it. It's just that it does happen. And we see that sometimes you don't treat a low and sometimes it bounces back. So I didn't mean to imply that we should be twiddling our thumbs while our kids are low.   Dr. David Kendall  16:48 Right? And you're absolutely right, the body does maintain some of those defenses as ecolog. What we're talking about here is there for those circumstances where the defenses are no longer adequate, someone loses consciousness, the ability to care for themselves. Alright,   Stacey Simms  17:05 let's let's get back on track here. Again, thanks for following me down that rabbit hole. And I'm always fascinated by studies and the process. Frank, let me ask you what so what is this is tell me a little bit about the product itself because we have other products on the market. Now you mentioned already the rescue kit that needs to be reconstituted, there's a nasal spray, there's a shot.   Frank Sanders  17:22 Now this was this is so second log is indicated for the treatment of severe hypoglycemia, and pediatric and adult hit and adult patients with diabetes. Ages, six years and above, we're going to be launching it with two forms available. We're one of those is going to be an auto injector a single dose auto injector and the other will be a single dose prefilled syringe, but both of which can be used immediately without requiring reconstitution that may allow for easier use at that moment when it's needed. And so you know, that really at a basic level, that's that's core to what what Zegalogue is. And we again, believe that based on the clinical study that David David has talked about the study data all three is that what distinguishes like a log is really the the median time to recovery of 10 minutes across all clinical trials and the consistency of response rates and adults in pediatric patients again, referring back to the data that David presented. So we're eager to introduce this product again and a couple short weeks here and offer this begin to offer this to patients and caregivers alike.   Stacey Simms  18:25 shelf life, you know, do I need to put in the fridge? Can you speak to that?   Frank Sanders  18:28 Very good question. So I'll talk a little bit about the storage and stability and David if I if there are details to add, please add but Zegalogue has a three year total shelf life when stored in refrigerated conditions in once removed from refrigerated conditions that can be kept at room temperature for up to 12 months. So stability and storage conditions of Zegalogue provide for options for people with diabetes, you're at risk of severe hypoglycemia to have this available at home, you know, in the refrigerated conditions for up to three years or out of you know, refrigerated conditions, either at home or away from home for up to a year and event that it's needed. So we believe that these dual storage conditions will be attractive to the lifestyle of patients with diabetes   Stacey Simms  19:12 couple of years ago, gosh, was it ready for the pandemic It must have been in the fall of 2019. So not too long ago, I ran into Ed Damiano of beta bionics and asked him you know what's going on? How are things and you know, they've got their own, we're actually talking to them in a couple of weeks. So let's talk about this as well. But my understanding correct me if I'm wrong, is that this is the brand of glucagon that they want to put in the dual hormone pump down the line. I don't know how much anyone can speak to any of this. So feel free to say no, because I know it's it's not coming. Now, this is not what we're talking about here To be clear, but this is one of the most anticipated developments in pump therapy. And I'm curious, can you speak to this is that correct?   Frank Sanders  19:57 Well, let me tell you this and then David, you could you can add to this as well. as you see fit, but yes, I mean that's a glucagon we consider this a platform therapy, you know. So obviously we're launching dasiglucagon in the form of Zegalogue as a rescue therapy for severe hypoglycemia. But it's the first of a long string of other potential launches with dasiglucagon. In the future you had mentioned, the partnership that we have in place with beta bionics that what I will say is that it's a great partnership, we're very pleased with the progress that we're making with this program, as we near the initiation of phase three trials. And so you know, everything is really moving forward at a steady rate there with that partnership. And we also have the David can touch on as well with dasiglucagon a program and place for use in congenital hyper and hyper insulin emia as well. So so the product itself is being studied for multiple applications to benefit multiple patients, not just with severe hypoglycemia, but with other with other specialty and rare disease areas. So it's just the beginning, if you will, it's like a log is this really the beginning for the use of the molecule much, much more to come over the next three to five years. Like Frank said, we're   Dr. David Kendall  21:05 really excited to be in the partnership with beta bionics I had in his team dasiglucagon is the platform and that Frank described, we see it as helping us leverage opportunities across what we call the hypoglycemic spectrum. So testing it, we hope in weeks and months ahead in phase three in the bio hormonal we call it artificial pancreas, the bionic pancreas, with beta bionics, but also for other hypoglycemic disorders, some in the setting of diabetes, like small doses that may be used for exercise or during illness, where it's not an emergency situation, all of these are planned investigations, but not yet part of the approved use of Zegalogue. Similarly, the condition, Frank alluded to congenital hyperinsulinism, where children are born with the dysregulated continuous secretion of insulin, so it's not diabetes, but they suffer recurrent and significant hypoglycemia, then there are very limited therapies. Thankfully, it's an ultra rare disease, but one that is really want for better therapies. And similarly, there are other health conditions where unexpected low blood sugars occur outside of the setting of diabetes. And we think because of some of the unique characteristics that deci glucagon has the stability at room temperature that it can and we hope will be applied, certainly in clinical studies, we hope in the future for patients with some of those conditions.   Stacey Simms  22:38 So it's interesting a couple of weeks ago, maybe a couple months ago, now we spoke to Leo Brown, who was on The Amazing Race, we will he lives with diabetes, I guess, but he has congenital hyperinsulinism. And his they basically removed most of his pancreas. And is that the kind of thing you're talking about where this would be an alternative treatment for somebody like that, perhaps?   Frank Sanders  22:57 Precisely. And so that's one of the approaches, historically to this condition, congenital hyperinsulinism was to remove the offending organ, the pancreas, which, as you witnessed, will leave somebody living with insulin deficient diabetes, so a form of type 1 diabetes that's surgically induced, but it was one of the only available therapies, we feel like that see, glucagon. And other approaches can counteract that hyperinsulinism, particularly in the youngest children, where there are the greatest dangers for these low blood sugars. And we hope either limit the need obviate the need for surgical interventions, and add to the tools that pediatricians in particular can use to manage this incredibly challenging disease.   Stacey Simms  23:45 And just back if I could to beta bionics, can you share anything about Gosh, I feel like we've just been waiting for this for a very long time. In terms of how it works. I know that, again, that's in clinical trials coming up. So you can't talk about a lot, but I'm just trying to picture what I you know, we fill the insulin pump with insulin, then we just fill the other chamber with the gun. I mean, it just to me seems so revolutionary. I'm trying to kind of parse any information that you can share with us.   Dr. David Kendall  24:10 Yeah, it's you're spot on Stacy. It's basically a two chamber pump. So think of how current insulin pumps are programmed. And in fact, with the hybrid closed loop systems, they were tied to continuous glucose monitoring to adjust the insulin delivery and those systems that have that capability. Add to that the same sort of functionality, but with glucagon, or in this case, dasiglucagon infusion that is regulated by the pump and by the glucose measurements. So with insulin being one side of that equation, when glucose does go lower, instead of simply shutting off the insulin and waiting for it to clear from the system, you have counterbalance, or the ability to counter regulate with the glucagon infusion and small little delivery boluses just Like insulin does for higher glucose is so similar to and in fact managed in much the same way as the insulin infusion for high glucose. The glucagon chamber and infusion wouldn't give those doses as glucose values declined, or were at certain levels,   Stacey Simms  25:15 if they're a second inset on the body for that I can't imagine goes to the same inset as the insulin.   Dr. David Kendall  25:21 Yeah, so So all of that is part of the development process. Obviously, these are two separate hormones. And one of the components of dasiglucagon, as Frank talked about is it's, it's stable in this so called aqueous solution, which for you will need that saltwater, the things that circulate in the body. So you know, while in theory, they could come through the same system, the plans in place, and the previous studies have been done with two separate fusion sites. But again, connected to the same pump system. So yeah, there's some sophistication involved. And I think back to pre CGM, when people said I have to wear this device now people often do quite well wearing two devices, their CGM and their pump. So depending on the ultimate design and approach to this, we certainly see the clinical promise as being something that's very encouraging. And then overcoming those engineering and technical challenges will be part of what faces our team with the beta bionics team. Really interesting. I   Stacey Simms  26:22 can't wait to talk to them to to get more information. Thanks for sharing what you could I appreciate? Absolutely. Let's talk about cost and access. What is this going to cost? I mean, I know that a lot of it depends on insurance. You started out by saying you were talking to payers, it's so sad that that's the first thing we have to talk about.   Frank Sanders  26:38 That's a good, it's a good question. These are obviously obviously amongst the first questions we always get when we're launching any product. So so we our strategy, from a pricing perspective, is the price Zegalogue at parity meaning add or are the same as existing products on the market? And we've based this strategy really on the value that psychologic provides? I think you're the bigger question is, is it going to be accessible for patients at launch. And you know, and really, that's, that's the reason why we are out actively engaging managed care customers today, both at payers and pbms, and Medicaid providers. And so I'll share that the the conversations have been have been very good that the profile Tagalog is being received very favorably, and we do expect to have favorable accesses, that is ecolog. At launch, that will continue to build as with any new product launch that will continue to build and improve over the first six months of launch. And I think as as you know, Stacey, from our conversations a little bit earlier, as I'm a caregiver myself, in my in my life, my my wife is been, you know, suffering for from stage four cancer for a number of years, and she's doing doing very well. But we we every day, interact with the healthcare system, and really have to think through barriers to access, whether that those are financial barriers or barriers to delivery of the product through specialty pharmacies, and we are really designing our patient support capability at Zealand. With that in mind, meaning, how do we make sure that when we're launching a product, we're able to provide the resources and forms of financial assistance and other resources to help address any sort of access barriers that may exist. So so there's really don't become transparent, so do we, so to speak, or, or, or a barrier for patients. And it's not just things like financial assistance, we are also putting programs in place to be able to make access easy in terms of product acquisition and distribution, for example, by looking at at home delivery solutions and other things so so we really are going to roll out a patient support system that is really fit for launching a product like this, in this error today where we also have to worry about COVID. So we're ready to go on all fronts in that area.   Stacey Simms  28:50 And we'll link up information as it comes out on patients assistance and access and things like that. But I'm always curious. And I I know the US health system is very complex. But why budget parity, why not launch and say we're gonna be $30? Less? How come nobody ever launches and says we're gonna come out and we're gonna make it affordable out of the box?   Frank Sanders  29:09 Yeah, I mean, we we look very carefully at multiple different pricing options and research it very carefully before we make a decision around it. And the price that we choose, really any company chooses. But in this case, I'll just talk about what Zealand does is the one that we that we think is going to ensure that we are going to get the best access possible for the product at a price point that that is representative of the value, the clinical value that the product brings to the market and that and that really led us to a parody pricing strategy, not a premium pricing strategy, not a discounting strategy, but one that is at parity with the rest of the market. And you know, again, based on the feedback that we've had in advance of setting the price and after setting the price and discussing with managed care organizations, we feel that we got it right.   Stacey Simms  29:56 Yeah, but you didn't get that from patients with all due respect. I can't imagine a patient said that's the right price.   Frank Sanders  30:01 Well, I think if we ask anyone, any consumer about about the price of the medicine, you know, the will will always get the response of, can we why that can cannot be lower? Can it be lower? That's absolutely fair.   Stacey Simms  30:14 Before I let you go, as I was looking through everybody's bio here, David, I can't let you go without asking you about the diabetes control and complications trial and the edic trial, I love to talk about these studies. I have I talked to a lot of parents whose children have been diagnosed, you know, recently, I run a very large Facebook group for Charlotte, North Carolina area. And I always say like, you've got to look at these these amazing trials that were done years ago, that show how much better things are getting. And I would love to just, I don't even know what I want to ask you. But I would love to give you the floor to just say that we didn't even know that a one c mattered, we didn't know the control made a difference. And to me, the edic trial is the one that shows me how much things are getting better. I do my right on any of that.   Dr. David Kendall  30:59 And well, you're talking to a very biased audience of one in me. So I grew up in the dcct edic era, I started in diabetes research in 1981, just as dcct was kicking off. So I've been either close to or seeing patients in dcct edic, through its entire history. And we're now 40 years out from the start of that trial. And yes, absolutely. These are 14 141 of the most courageous, incredible people who committed literally decades of their life to helping us understand what benefits may come from improving glucose control, particularly early on in the course of type 1 diabetes. And what I love is that many of these are patients I know to this day who are celebrating their 17th and 18th birthdays, I'm in the setting of type 1 diabetes. And unequivocally dcct, in my mind is one of the 10 great research studies in medicine, it demonstrated the benefit of having blood sugars as well controlled as possible, as early in the course of diabetes as possible. and maintaining that for as long a period as possible that I always catch that by saying, you know doing it as rationally and safely as possible. And what we're talking about here today, meaning severe hyperglycemia was first really made evident to us in the dcct. where, you know, on average, every patient had a severe event per year during the study, because we were working so hard to control glucose. So it ties back to our topic. And yeah, for the next three and a half hours of this podcast. I'd be happy to add more if you'd like. Frank will never invite me back. So   Stacey Simms  32:48 Oh, no, no. Okay, wait, one more question about the dcct edic. Is there a follow up? Will we get another one of all these people soon? Or is it kind of   Dr. David Kendall  32:58 it continues to this day, and there are various components to it, it is much less thorough and intensive in terms of the follow up, but the 30 and soon 40 year follow up of those patients has been and will be published and presented as the years go ahead. So this is the study that probably will only end when we run out of investigators and individual volunteers for the study.   Stacey Simms  33:26 I gotta say I look at those studies. And I'm so glad you mentioned the brave and wonderful people in them. Because that has my son was diagnosed right where he turned to 14 years ago. And what they have done, has changed his outcome. It's just fabulous. So thank them next time you see I'm telling Stacy and Charlotte. Before we finish it, was there anything about that video segment that we didn't cover?   Dr. David Kendall  33:48 Yeah, I'll close and then toss it back to Frank. But I think one of the things that first attracted me to Zealand but also the work around Zegalogue is that hyperglycemia really remains one of those conundrums, one of the rate limiting features of managing diabetes most effectively, and bringing forth the two legs Zegalogue to help patients have the peace of mind make a plan for when the unthinkable might happen, a severe event. And doing so with the data that we've talked about where you have this very rapid and reliable response to Desi glucagon and the clinical trials for this, like many other emergency therapies, you don't want to have it, but you certainly want it on hand if you need it. So all of that, to me is central to what we're doing, not just with the clinical studies, but with the clinical launch of Zegalogue.   Frank Sanders  34:43 Now very good. I would just just close by saying what excites us about this launch in particular, is that there are 4 million people in the United States with diabetes on multiple daily injections of insulin and these patients are at higher risk of having severe hypoglycemic event. And despite the fact that there are 4 million people in the US with diabetes on on multiple daily doses, only approximately 14% of that population is prescribed a glucagon rescue therapy. So So what's been interesting is and positive is this is with the introduction of newer innovative therapies over the last year and a half, two years, more people are becoming aware of these treatment options, and the market is growing by by 10%. And we believe that that's really just the beginning is the you know, having Zegalogue in the market, that's yet another innovative option has the ability to further grow this by increasing awareness. And we're excited about the positive impacts effect that will have on patients and their caregivers.   Stacey Simms  35:44 Well, Frank Sanders, Dr. David Kendall, thank you so much for joining me and explaining all this. I really appreciate you spending so much time with me. Thank you.   Announcer  35:56 You're listening to Diabetes Connections with Stacey Simms.   Stacey Simms  36:02 I will link up more information about Zegalogue. And about the DCCT EDIC trials as well. And if you haven't heard our episode, evidence-based hope, I highly, highly, highly recommend it, especially for newer diagnosed people and families. It's not just a look how far we've come kind of thing. But it also puts in perspective, a one see numbers, things right now that you can do to live a long and healthy life with diabetes. And it doesn't mean that you need to always have you know, a super low A1C I think especially as parents, we often lose track of the happy, good life thriving with diabetes, because we're so focused on getting that that time and range and those super low a one season those trials really put it in perspective for me, and what you need to really live well. And it's not what a lot of people on Facebook, what have you believe in just a second, I want to give you an update on how Benny's doing and wrestling has started. And oh my goodness, but first Diabetes Connections is brought to you by Dexcom. And it really is hard to remember what things were like before we started using Dexcom. I had a woman asked me what was our plan for kindergarten. And we were still a good four or five years away from Dexcom at that point, so it's really interesting to look back because it is so different. Now we were doing something like 10 finger sticks a day when Benny was going to kindergarten. I mean, even when he got older, we still did at least six to eight every day more when he wasn't feeling well or something was off. But with each iteration of Dexcom we've done fewer and fewer sticks. The latest generation the Dexcom g six eliminates finger sticks for calibration and diabetes treatment decisions. Just thinking about Benny's little worn out fingertips makes me so glad that Dexcom has helped us come so far. It's an incredible tool and Benny's fingertips are healthy and smooth, which I never thought would happen when he was in kindergarten. He for glucose alerts and readings from the G6 do not make symptoms or expectations. Use a blood glucose meter to make diabetes treatment decisions. learn more, go to Diabetes connections.com and click on the Dexcom logo.   Aren't if you've been listening for a long time or you follow me on social media, then you know that Benny is finishing up his sophomore year in high school and he started wrestling when he was a freshman he got injured right at the beginning of the season. He tore his meniscus. And he was out for the 2020 season, which was right before COVID. They were able to get a full season in and he was part of the team. He was like manager and he went on crutches to every match. And he was pretty incredible season they won the state championships for the first time. It was just a really fun year, but he had to sit on the sidelines. So that was kind of a bummer. But he is back. He's worked really, really hard. And of course with COVID they kept putting off the season. And we always thought there is absolutely no way there's going to be wrestling. So he actually went out and got a job. I've mentioned before he got his vaccine, he's at a grocery store. And he's been working really hard. And so when wrestling came back, it was kind of a tough decision to make. But he was able to work it out with his work schedule. And this kid is so busy, and they had their very first match. As you're listening it would be last week. So Benny had his very first you know, match. But that's not the story. I want to tell you what was amazing. And by the way, I can't watch wrestling. Do you watch wrestling if your kids wrestle? I can't watch any sport my kids play because I'm the loud mouth mom. So I'm always the one like trying to look at her phone. So I'm not screaming I'm not being rude. I'm not not paying attention. But I'm shockingly I have comments. So I try to keep them to myself. But wrestling is just so gross. It's so rough. I can't stand it. But they come out on the mat and the ref comes out and he's like you know our loved ones with clean Theodora and I'm looking at the ref and I immediately Look at his belt line because there's a T slim pump. He's wearing a T slim next to you know, it's right on his back. And I was sitting very close. So part of me wanted to yell like, excuse me. Hello, sir. But I didn't do anything. I didn't say anything. I did take a couple of pictures which was probably very inappropriate, this poor man, but I couldn't help myself. It was so exciting. They faced two different schools. So it was the match that He was in and then there was another match. They didn't wrestle in, and my daughter had just come home from college. So after that first match, I said goodbye. I said, Okay, if I go and I left, I went home because my daughter, Lea, I haven't seen her in a while. So I wanted to run home to her. And I couldn't talk to the ref, because he went from one match. Immediately, he crossed the gym and went to the other match. Then he came over to kind of talk to me as I was leaving, and I told him and I, you know, it wasn't sure if he'd be like, Mom, it's so lame. You know, who cares. But he lit up, he was excited, and he wants to go say hi, but it was just such a busy night. And these reps are just working, working, working that, you know, as I said, I didn't get a chance to talk to him, but he didn't get a chance to talk to him. So I'm hoping that we see him again, as these wrestling matches go on. But hey, if you're listening ref in Mecklenburg County, North Carolina, drop me a line. And thank you very much for not noticing the bananas lady behind you taking pictures of your back.   Before I let you go quick note I will be speaking at the camp Nejeda event survive and thrive. That is on June 5. It's a virtual event. We are looking forward to friends for life in July, I will be there I'm not sure in what capacity as a speaker yet waiting to hear from them. Because it's very different this year, far fewer speakers, but I will be there as a vendor. So I hope I can meet at least some of you. And please join me tomorrow. If you're listening as this first drops on Wednesday, May 12, as I'm doing every Wednesday in May 4:30pm. Eastern on my Facebook page Diabetes Connections i will be doing in the news, my newscast that I'm trying out and then we'll turn that around and drop it as podcast episode. They're very short. My goal is to make them not only less than 10 minutes, hopefully less than eight or seven minutes. I'm really trying to keep it very tight and just have some headlines. But the top stories of the past week, all types of diabetes really be useful for you to make it bite size make it relevant. So let me know what you think. Thank you, as always to my editor John Bukenas from audio editing solutions. Thank you so much for listening. I'm Stacey Simms. I'll see you back here in just a couple of days. Until then, be kind to yourself.   Benny  42:19 Diabetes Connections is a production of Stacey Simms Media. All rights reserved. All rounds avenged

Today on Terranauts the second part of my conversation with the Quintessential Terranaut Dave Kendall. We talk about Dave's career managing increasingly larger and more international programs until he ended up as the chair of one of the United Nation's largest and most active committees. Not bad for a lad from Twickenham.

Could this be your biggest breakthrough to Faith in Yourself?  David Kendall shares what he's found to be the biggest "truth bomb" that explodes to unleash confidence in who you are!  Support the show

This week on Terranauts we're taking a break from our regular run of the Terranauts Guide to Leaving the Planet to bring you a fascinating interview with David Kendall who could be described as the quintessential Terranaut. On Terranauts we often talk about the fact that no gets to space alone. We are fond of saying that space is a team sport, not only for individuals but for countries as well. Over the course of the past season and a half we have certainly talked to our share of Terrantauts with extensive international experience. But I think It's pretty rare to have one with the pedigree of today's guest. Dr. David Kendall has not only been at the forefront of major international collaborations for the last 40 years, he has also been a Vice President of the International Astronautical Federation AND for two years he was the Chair of the UN Committee on the Peaceful Uses of Outer Space.

This week, David Kendall, Dominic Horne, and Don Thomsen face off in perhaps our first match with contestants from three different countries! Listen in as they kick off Wave 17.

What are the most pressing challenges confronting governments, industry and civil society in terms of building capacity for implementing international space sustainability guidelines, and what steps should each of these three sectors prioritize to build such capacity? This panel of leading international experts shared their thoughts on how governments, industry and civil society can jointly build capacity in the space community to support the implementation of the international guidelines for space sustainability recently adopted by the UN. For more background information on these guidelines, see our SWF Factsheet.                                                  Panelists  Government  Niklas Hedman, UN Office for Outer Space Affairs, Austria Andre Rypl, Ministry of Foreign Affairs, Brazil         Keren Shahar, Ministry of Foreign Affairs, Israel          David Turner, Department of State, United States  Industry Aarti Holla-Maini, EMEA Satellite Operators Association, Belgium Therese Jones, Satellite Industry Association, United States  Daniel Oltrogge, Space Safety Coalition, United States    Charity Weeden, Astroscale, United States                                                            Civil Society  David Kendall, Outer Space Institute, Canada Jean-Jacques Tortora, European Space Policy Institute, Austria  Guoyu Wang, Beijing Institute of Technology, China  Danielle Wood, Massachusetts Institute of Technology, United States

John visits David Kendall, Founder and CEO of Bold Legal, at his office in Denver, Colorado to talk about how his passion for cyclocross and his career as an attorney both involve leadership skills, taking risks, and how both satisfy his desire to pushing limits!

#RedVestBrigade #Trump2020 #President Trump #PeteSantilli #TRUMPTWEETS #Corona Virus, #CoronaVirusUpdate THE PETE SANTILLI SHOW Episode #1910 - Thursday - April 30, 2020 - 6PM Live Broadcast Link: https://youtu.be/C3EAJ02tO0k    MAJOR SHOCKING REVELATIONS ON DOJ & FBI COVER-UP OF SETH RICH INVESTIGATION 1910-6P More evidence confirms more FBI and Mueller gang lies and cover ups. This time a Deep State Anti-Trump former Assistant US Attorney claimed under oath that the FBI did examine Seth Rich’s computer and that she met with an FBI Agent and prosecutor from the Mueller gang. This indicates the meeting should have been recorded in a form 302 but the FBI continues to claim no records related to Seth Rich are available .. MAJOR SHOCKING REVELATIONS ON DOJ & FBI COVER-UP OF SETH RICH INVESTIGATION – The Pete Santilli Show http://ow.ly/PzXi30qC9dn  GUEST: Ty Clevenger describes himself as a - Former-cop, Former-journalist, disgruntled lawyer, muckraking blogger, and cheerful optimist. The Dallas Morning news said about Mr. Clevenger: Ty Clevenger is a marked man, not in organized crime circles, but in the legal world of judges and lawyers. He has been called the craziest but bravest Texas lawyer who took on Ken Paxton, and federal judges.. All of these things may be true but they also make him a National treasure. Mr. Clevenger downplays his role in the struggle to reform our Judicial System by simply referring to himself as "just a Lawyer and blogger" but in 2016 he was one of the first high profile attorneys to file grievances with the D.C. Bar and with bar associations in New York, Maryland and Arkansas against the following notables: Hillary Clinton, about her email problem.  Her top aide, Cheryl Mills over same.   FBI Director James Comey and former U.S. Attorney General Loretta Lynch for mishandling the email case. Clinton lawyer David Kendall for deleting the Clinton emails.   http://lawflog.com/?author=1    

David Kendall is our newcomer this week, battling it out with our returning champ. We hope you’re in the mood for some laughs, because this episode certainly has some!

THE PETE SANTILLI SHOW Episode #1708 - Friday - December 13, 2019 - 6PM  Live Broadcast Link -  https://youtu.be/T_M_ptgAfR0  Death of The Deep State: Attorney Ty Clevenger Poised To Legally Dismantle Entire Russia Hoax -1708 6PM For two years, Ty Clevenger blogged about allegations that Democratic National Committee staffer Seth Rich — not the Russians — was responsible for providing embarrassing DNC emails to Wikileaks. He provided the U.S. District Court in Brooklyn with clear evidence that FBI officials were hiding records about Mr. Rich, who was murdered in Washington, D.C. in the summer of 2016. Bank on it, says Clevenger: The FBI is hiding records about Seth Rich GUEST: Ty Clevenger is a 49-year-old lawyer, East Texan raised on a small farm, in Aggie. He practiced law in Collin County for a time. Now he handles mostly civil rights cases in Texas.   One reporter described Mr Clevenger as a fearless, saber-toothed legal hit man for what he believes is right. Among those in his cross hairs: lawyers, federal judges, presidential candidates, the Texas attorney general, and in some Texas towns even lowly city council members.  Ty is a former reporter, a former police officer and, since 2001, a lawyer. "I don't like watching people get away with things because they're powerful," he says, are words he tries to live by. Mr. Clevenger downplays his role in the struggle to reform our Judicial System by simply referring to himself as  just a Lawyer and blogger but in 2016 he was one of the first high profile attorneys to file grievances with the D.C. Bar and with bar associations in New York, Maryland and Arkansas against the following notables: Hillary Clinton, about her email problem. Her top aide, Cheryl Mills over same.  FBI Director James Comey and former U.S. Attorney General Loretta Lynch for mishandling the email case. Clinton lawyer David Kendall for deleting the Clinton emails.  http://lawflog.com/   E-Militia Article:  Death of The Deep State: Attorney Ty Clevenger Poised To Legally Dismantle Entire Russia Hoax – E-Militia News http://ow.ly/4RQS30q1J8a  Save Our APP To Your Smartphone! https://one.cards/PeteSantilli Morning Prayer Requests: http://petelive.tv/prayer 

This week’s match features Christian Engel, David Kendall, and Marcus Plaisance. It’s the penultimate episode of wave 8 - enjoy!

THE PETE SANTILLI SHOW Episode #1656 - Friday - October 18, 2019 - 6PM Live Broadcast Link - https://youtu.be/hlS-esJ1pd0  EmailGate: Epic Battle Between FBI & DOJ In Progress; Covering Up Murder of DNC Operative - 1656-6P Despite Prior FBI Statements that Seth Rich’s DNC Computer and Emails Were Investigated, FBI Now Claims No Related Docs in FOIA Request.  Attorney Requesting Documents Demands Court Step In. Texas businessman Ed Butowsky filed a lawsuit where he outed reporter Ellen Ratner as his source for information on Seth Rich. The DNC operative was murdered in the summer of 2016 in Washington DC. His murder was never solved. According to the lawsuit Seth Rich provided WikiLeaks the DNC emails before the 2016 election, not Russia. This totally destroys the FBI and Mueller’s claims that Russians hacked the DNC to obtain these emails. E-Militia Article: EmailGate: Epic Battle Between FBI & DOJ In Progress; Covering Up Murder of DNC Operative http://ow.ly/vMVb30pK70Y  GUEST: Ty Clevenger is a 49-year-old lawyer, East Texan raised on a small farm, in Aggie. He practiced law in Collin County for a time. Now he handles mostly civil rights cases in Texas.   One reporter described Mr Clevenger as a fearless, saber-toothed legal hit man for what he believes is right. Among those in his cross hairs: lawyers, federal judges, presidential candidates, the Texas attorney general, and in some Texas towns even lowly city council members.  Ty is a former reporter, a former police officer and, since 2001, a lawyer. "I don't like watching people get away with things because they're powerful," he says, are words he tries to live by.  Mr. Clevenger downplays his role in the struggle to reform our Judicial System by simply referring to himself as  just a Lawyer and blogger but in 2016 he was one of the first high profile attorneys to file grievances with the D.C. Bar and with bar associations in New York, Maryland and Arkansas against the following notables: Hillary Clinton, about her email problem. Her top aide, Cheryl Mills over same. FBI Director James Comey and former U.S. Attorney General Loretta Lynch for mishandling the email case. Clinton lawyer David Kendall for deleting the Clinton emails.

David Kendall will soon be stepping down from the role of Bishop after 11 faithful years. Listen as he joins us to discuss life after the work of a Bishop and his new book on women in leadership, Follow Her Lead! Listen to Bishop Kendall's first episode: https://fmcradio.podbean.com/e/011-immigrants-bombs-and-bishops-with-bishop-david-kendall/ Pre-order Follow Her Lead: https://fmcusa.org/bookstore/product/follow-her-lead-pre-order/ Leave a voicemail for the show by calling: (914) FMC-USA1 Please like the show page at www.facebook.com/fmcradio and follow us on Twitter @FmcRadioShow Email Josh: josh@befreemc.org

WARNING - This episode is a lot of fun. Don't listen unless you want to have a good time :-) Chris is BACK! It felt so good to get my brother from another mother back in the studio. He's hosting this weeks game. It's Carmela and Jonathan vs. guests David Kendall and Adam Fried. Make sure you listen all the way to the end this week or you're going to miss one of the funniest moments in a long while! Also - don't forget to search for Trivial Warfare Blitz, our new lightning round game. You can find it on any Podcast app. the shows are 15 minutes or less and we're having a lot of fun with it.

WARNING - This episode is a lot of fun. Don't listen unless you want to have a good time :-) Chris is BACK! It felt so good to get my brother from another mother back in the studio. He's hosting this weeks game. It's Carmela and Jonathan vs. guests David Kendall and Adam Fried. Make sure you listen all the way to the end this week or you're going to miss one of the funniest moments in a long while! Be sure to subscribe to Trivial Warfare Blitz on your favorite Podcast App! --- Send in a voice message: https://anchor.fm/trivial-warfare-trivia/message

Today’s SpaceQ podcast is panel discussion from the recent Canadian Science Policy Conference. The panel, titled "How Canada Can Create a Sustainable National Space Infrastructure” was organized by Michelle Mendes of the Space Advisory Board and features members of the Space Advisory Board. Each panel member discussed a specific area for the theme and were very articulate in getting their point across. The panel was moderated by: (2:21) Dr. David Kendall, Past Chair of the United Nations Committee on the Peaceful Uses of Outer Space. The panelists; (6:16) Kate Howells, Global Community Outreach Manager and National Coordinator for Canada, The Planetary Society (12:18) Dr. Gordon Osinski, NSERC/MDA/Canadian Space Agency Industrial Research Chair in Planetary Geology, Western University (21:41)Dr. Michael Pley, President, Pley Consulting Inc. (29:35) Dr. Lucy Stojak, Executive Director, Mosaic (43:07) Short questions and answer session. I would like to thank to Canadian Space Policy Centre for providing us this audio recording. Listen in.

Happy Monday! Your week starts off with David Kendall, Nicolle Neulist, and Brett Chandler! As always, they attempt to name as many items as they can from lists in all categories! You can find our Patreon at patreon.com/thejeopardyfan/. You can also follow us on Twitter at @CompleteList and on Instagram at @completethelist, and please review us on your favorite podcasting app!

Spenser Villwock interviews David Kendall, Director of Industry Affairs at IEC Platinum Partner, ABB, Electrification Products Division. He is a Code Geek (term of affection), and an insightful and thoughtful industry expert. David is truly a great partner in advancing the electrical and systems trade. #WeAreIEC

My guest this week is David Kendall, the Chair of the United Nations Committee on the Peaceful Uses of Outer Space. David is a faculty member of the International Space University and was a Senior Executive at the Canadian Space Agency during his long career. While trained as a scientist, David has become an important leading expert on global space policy and law. Today we’re going to first discuss the current state of space policy in Canada followed by the global perspective.

David Kendall, Dustin Resch, Brian Nieves

Your Sins are Forgiven

Your Sins are Forgiven

Your Sins are Forgiven

Welcome to Season 2 of BEAT MY GUEST - the trivia podcast where you can play along at home. This week's guest is DAVID KENDALL. He will face four rounds of four questions in a wide range of topics. Along the way, he will wager points to set the bar for you, the listener, to play along and - if you can - BEAT MY GUEST.  BECOME A PATRON and get a chance to win a spot in the hotseat... Go to PATRON.PODBEAN.COM/beatmyguest for details! Twitter:@BMGpod   Music: http://www.purple-planet.com BRAND NEW! - FACEBOOK FAN GROUP - CLICK HERE

David Kendall, Kaberi Chakrabarty, Joe Nguyen

Aria Gerson, David Kendall, Trevor Mahoney, Fred Vaughn

Wesley Wells, Matthew Kimberlin, and David Kendall

Bishop David Kendall joins us to discuss a matter most Christian leaders do their best to avoid: the world of politics. But with bombs being sent to foreign lands, immigrants living amongst us, and injustices occurring in the world on a seemingly increasing basis, shouldn't we speak up about some of the issues that matter most? Today, Bishop Kendall will unashamedly take on all of these issues and more... "Looking for America" is written by Switchfoot & Lecrae Leave a voicemail for the show by calling: (914) FMC-USA1 Please like the show page at www.facebook.com/fmcradio and follow us on Twitter @FmcRadioShow Email Josh: josh@befreemc.org

with Andy Saunders and David Kendall

David Kendall, Senior Fellow for Health and Fiscal Policy at centrist think tank Third Way, discusses the likelihood of future health care legislation. He also explains what the Trump Administration can do to change U.S. health care policy without congressional action and how those changes could affect American businesses.

Changes are afoot in the private rented sector in Scotland and Wales and there may be implications for other parts of the UK. The deadline for landlords and agents to register as part of Rent Smart Wales was 23 November 2016. Scotland has had a national landlord register since 2006, now no fault possession is being abolished and consultation on a new standard tenancy limiting rent increases with new forms and notices continues until 25 December 2016. How are landlords and tenants responding to these changes? Scotland banned letting agent fees in 2012, but is the ban working? Now Westminster is following suit, will politicians south of the border borrow more policy initiatives? Richard Blanco is joined by Bethan Jones from Rent Smart Wales, David Kendall who runs Hamilton based agency Lets Makes Homes, James Battye from Shelter Scotland and Richard Lambert from the National Landlords Association to explain, untangle and evaluate this shifting landscape. Inside Property is produced in collaboration with the National Landlords Association.

Prior to the Voting Rights Act of 1965, African-Americans across the South were denied the right to vote through the use of poll taxes, literacy tests and other tactics of suppression.  In 1964, David Kendall was a 20-year-old Indiana college student. In this episode, he recalls coming to Mississippi to participate in the voter registration drive known as Freedom Summer. Over the course of that summer, Kendall would be jailed multiple times. He shares his memories of that first arrest and being introduced to the best cheeseburger in Holly Springs.  In preparing for Freedom Summer, Civil Rights workers received extensive training in a variety of tactics, but he explains how growing up on a farm proved surprisingly useful in helping to gain the confidence of black farmers in the Delta.   Image: Voter Registration Holly Springs, McCain Library & Archives, USM

Washington D.C. - Featuring Andrew Biggs of AEI, David Kendall of Third Way, Maya MacGuineas of the Committee for a Responsible Federal Budget, and moderated by Margaret Hostetler of the Ways and Means subcommittee on Social Security.

Noted attorney David Kendall '66 talks of defending the First Amendment, his law career, his time at Wabash, and the Freedom Summer of 1964. (Episode 30)

David Kendall, Director of the Space Studies Program, this year taking place in Montreal, tells Carmel Kilkenny about the International Space University

David Kendall says the summer space program will offer a wide array of multi-disciplinary courses.

News. Cinéma : Godzilla de Gareth Edwards, Amazing Spider Man Le Destin d’un Héros de Mark Webb. BD/Comics : Dead Boy Detectives de Toby Litt et Mark Buckingham, La Revue Dessinée. Série : Melissa & Joey de David Kendall et Bob Young. Salut à toutes et à tous. Bienvenue pour ces nouvelles chroniques de Kultur Breakdown. Avant toutes choses, …

February 25, 2014 - Following Jesus: Undoing the Devil's Mischief by David Kendall

February 25, 2014 - Following Jesus: Undoing the Devil's Mischief by David Kendall

Guest: David Kendall, MD Host: Steven Edelman, MD The assessment of intensive glycemic control in preventing cardiovascular disease is unclear. Discrepancies in recent clinical trials such as ACCORD, ADVANCE, PROactive and UKPDS 80 may reflect difference in study design and patients, versus glycemic control. How can using the Archimedes model illuminate this quandary? Join host Dr. Steven Edelman and his guest, chief scientific and medical officer of the American Diabetes Association, Dr. David Kendall, as they discuss the effect of glycemic control on macrovascular outcomes in patients with diabetes.